系统性肺癌治疗的肺毒性
本文综述了非小细胞肺癌系统性治疗相关肺毒性的表现与处理。细胞毒化疗中的紫杉烷类可致间质性肺病样反应,酪氨酸激酶抑制剂(TKI)相关间质性肺病偶呈急性间质性肺炎伴高死亡率,免疫检查点抑制剂(ICI)肺炎发生率在某些临床情境下高达19%且仅半数对激素有效。临床医生需识别并应对药物性肺毒性。
要点
- 紫杉烷类相关肺炎罕见,多数对激素有效,但有致死病例报告。
- EGFR-TKI相关间质性肺病罕表现为急性间质性肺炎,进展快、死亡率高。
- ICI肺炎在高等级时可致呼吸衰竭,仅半数患者对激素治疗有改善。
核心结论
- 随着非小细胞肺癌系统治疗发展,临床医生必须识别并应对药物性肺毒性。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- 紫杉烷类肺毒性表现为间质性肺病型反应,包括呼吸困难加重、干咳、发热和双肺间质浸润。
- EGFR-TKI相关间质性肺病罕表现为急性间质性肺炎,伴快速进展的呼吸衰竭和高死亡率。
- ICI肺炎在某些临床情境下报告发生率高达19%,仅半数患者对激素治疗有改善且死亡率高。
关键数值与推荐
- 紫杉烷类诱导肺炎发生率罕见,许多患者对激素治疗有反应,但已有致死病例报告。
- ICI肺炎报告发生率在某些临床情境下高达19%。
- ICI肺炎仅半数患者对激素治疗有改善。
临床怎么用
- 使用紫杉烷类、EGFR-TKI或ICI治疗的非小细胞肺癌患者出现呼吸困难、干咳或低氧时,应警惕药物性肺毒性。
局限性
- 本文为综述,摘要未报告检索范围及纳入研究的样本量与设计细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung cancer is the leading cause of cancer-related deaths worldwide. As new therapies are developed, it is important to understand the pulmonary toxicities associated with systemic lung cancer therapies. Cytotoxic chemotherapy regimens for NSCLC often include taxanes. Pulmonary toxicity from taxanes presents as an ILD-type reaction characterized by increasing dyspnoea, dry cough, fever and bilateral pulmonary interstitial infiltrates. The incidence of taxane-induced pneumonitis is rare, and many patients respond to steroid therapy; however, fatal cases have been reported. Patients with NSCLC are routinely tested for the presence of tumour oncogenes to determine their candidacy for targeted therapies, such as TKI. EGFR-TKI can cause pneumonitis characterized by progressive dyspnoea and hypoxia. EGFR-TKI-associated ILD rarely presents as an AIP with rapidly progressive respiratory failure and high mortality rates. The most recent development in lung cancer therapy has been the discovery of immune checkpoint inhibitor (ICI). ICI pneumonitis has been increasingly recognized as a common complication of ICI therapy, with reported incidence as high as 19% in some clinical settings. Early-grade ICI pneumonitis may be asymptomatic; however, high-grade ICI pneumonitis can result in progressive dyspnoea, hypoxia and respiratory failure. ICI pneumonitis is unique in that only half of the patients will improve with steroid treatment, and mortality rates are high. As treatment of NSCLC evolves, providers must be able to recognize and respond to the development of drug-induced pulmonary toxicities.
引用
- Long K, Suresh K. Pulmonary toxicity of systemic lung cancer therapy. Respirology. 2020. PMID: 32729207. doi:10.1111/resp.13915
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。